Whether your personal interests are in supporting innovation, bringing lifesaving biomedical products to patients, training the next generation of biomedical leaders or fueling our economy, the Center for Biotechnology provides a vehicle to accomplish great things. Things that matter. Things that change, and save, lives.
Your involvement is an essential part of our future. Please consider a gift to the Center for Biotechnology which will help fuel innovation by ensuring that lifesaving technologies make it out of research labs and into the hands of patients.
Give to the Center for Biotechnology online through the Stony Brook Foundation. Contributions can be made to our Fund for Excellence. More information about donating through the Stony Brook Foundation can be found here.
Free HHS Small Business Program Conference on April 26-30
April 7, 2021
Are you a small business entrepreneur who is developing a product or service that has the potential to improve human health? Join the free 2021 HHS Small Business Program Conference being held virtually on April 26-30 to learn how to apply for small business funding, and much more!
This year’s conference will explore the theme Diverse Perspectives SEEDing Impactful Innovations, with a special emphasis on recruiting new innovators from diverse backgrounds.
Learn how to apply for small business funding, discover helpful resources to navigate your journey to commercialization, and much more. You’ll also have the chance to schedule a 15-minute meeting with small business program staff and special topic experts to get your questions answered. Learn more and register!
The Center for Biotechnology is pleased to announce a request for proposals for our Research Evaluation and Commercialization Hub (REACH) award program. Awards will be in two categories: Feasibility ($50k/12mo) and Proof of Concept ($100K/12 mo.) Details on the full funding program overview and proposal guidelines can be found here.
The development of promising innovations often stalls due to limited early-stage funding to address translational uncertainties. The Center for Biotechnology's Research Evaluation and Commercialization Hub (REACH) award program bridges the translation gap between biomedical discovery and their development toward commercial goals. Program funding is intended to determine feasibility, develop proof-of-concept, and ultimately lead to follow-on funding, a strategic partnership, or company formation.
The REACH program supports faculty and postdoctoral researchers in translating bio-based, bio-convergence, and bio-medical research discoveries by providing targeted funding and strategic guidance to bridge the translation gap between discovery and development for commercialization.
[post_title] => Funding Opportunity: Research Evaluation and Commercialization Hub (REACH)Awards
[post_excerpt] => The Center for Biotechnology is pleased to announce a request for proposals for our REACH award program. Awards will be in two categories: Feasibility ($50k/12mo) and Proof of Concept ($100K/12 mo.)
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => news-reach25
[to_ping] =>
[pinged] =>
[post_modified] => 2025-03-24 12:11:36
[post_modified_gmt] => 2025-03-24 16:11:36
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://centerforbiotechnology.org/?p=4804
[menu_order] => 0
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[1] => WP_Post Object
(
[ID] => 4488
[post_author] => 4
[post_date] => 2024-10-24 10:45:00
[post_date_gmt] => 2024-10-24 14:45:00
[post_content] =>
Governor Kathy Hochul has unveiled plans for New York BioGenesis Park, a groundbreaking $430 million Cell and Gene Therapy (CGT) Innovation Hub in Nassau County, Long Island. To be developed by The Albanese Organization, Inc., this state-of-the-art facility would catalyze CGT research, development, clinical manufacturing, and commercialization across New York State. With a historic $150 million state investment—the largest nationwide for a cell and gene therapy hub—NYBGP would accelerate the delivery of new therapies from lab to patient in New York's diverse communities. This transformative hub aims to establish New York as the leading global destination for CGT innovation, driving economic growth, attracting top talent, and revolutionizing patient care statewide and beyond.
The Center for Biotechnology is thrilled to be counted as a partner in this effort, and is looking forward to working with our colleagues in the initiative to help catalyze and accelerate life-changing therapies.
New York BioGenesis Park is envisioned as a cutting-edge, full-service campus dedicated to advancing cell and gene therapies and accelerating their commercialization. At full build-out, the 700,000-square-foot park would create an end-to-end Cell and Gene Therapy innovation and supply center, featuring interconnected areas for public engagement, research, manufacturing, and collaboration.
A cornerstone of New York BioGenesis Park is its incubator, supported by a $50 million investment from ESD's Long Island Investment Fund. This facility will empower early-stage therapeutic developers by offering state-of-the-art wet lab space, shared equipment, office space, and other essential resources. This nurturing environment will provide Cell and Gene Therapy companies with access to specialized equipment, mentoring, and stage-appropriate financial guidance. As a critical component of New York BioGenesis Park, the incubator is poised to catalyze the growth of promising Cell and Gene Therapy companies by providing them with resources and support, unlocking their potential for innovation and success.
New York BioGenesis Park would foster strong ties with academic and medical institutions throughout New York, creating a robust ecosystem for Cell and Gene Therapy innovation. Collaborating with the Empire State Cellular Therapy Consortium and world-class institutions like Cold Spring Harbor Laboratory, the Feinstein Institutes, Northwell Health, Roswell Park, Stony Brook University, Weill Cornell, Columbia University and others around the state, New York BioGenesis Park would enhance research synergies and accelerate medical breakthroughs. This ecosystem would bring together experts in advanced Cell and Gene Therapy therapies, offering specialized facilities, services, and resources to both tenants and collaborating institutions. By facilitating cutting-edge science, innovative technology development and novel approaches to clinical trials, New York BioGenesis Park would ensure New York's institutions remain globally competitive in groundbreaking Cell and Gene Therapy research and commercialization.
[post_title] => Long Island to be location for Nation-Leading Cell and Gene Therapy Innovation Hub: New York BioGenesis Park.
[post_excerpt] =>
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => long-island-to-be-location-for-nation-leading-cell-and-gene-therapy-innovation-hub-new-york-biogenesis-park
[to_ping] =>
[pinged] =>
[post_modified] => 2025-02-26 16:35:20
[post_modified_gmt] => 2025-02-26 21:35:20
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://centerforbiotechnology.org/?p=4488
[menu_order] => 0
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[2] => WP_Post Object
(
[ID] => 4291
[post_author] => 4
[post_date] => 2023-09-12 09:36:16
[post_date_gmt] => 2023-09-12 13:36:16
[post_content] =>
The Long Island Network for Clinical and Translational Science (LINCATS) will award two $25,000 pilot grants to fund innovative translational science research projects. Each project should address a critical issue in translational science, and be performed over one year. The awards are intended to facilitate new research directions and ultimately result in competitive external proposals.
Postdoctoral fellows and faculty affiliated within LINCATS Brookhaven National Laboratory, Cold Spring Harbor, Northport VA Medical Center and Stony Brook University are eligible. Single or multi-investigator teams are invited to apply. Submission Deadline 16 October 2023. Application pdf must be uploaded online.
Visit stonybrookmedicine.edu/LINCATS/LINCATSPilots for the Submittable submission link and more details.
The Center for Biotechnology has announced the appointment of Dr. Dee Dao as Associate Director for Business Development and Investment. In her new role, Dr. Dao will serve as the primary contact on issues related to research, technology development and commercialization for the Center for Biotechnology. Additionally, Dr. Dao will foster new collaborative relationships in order to bolster sponsored research agreements and strategic alliances.
Prior to joining the CFB, Dr. Dao served as a Venture Associate for the NYU Innovation Venture Fund, where she focused on investment opportunities in life science and healthcare. Prior to NYU, Dr. Dao was at the Ludwig Institute for Cancer Research where she contributed to early oncology therapeutic development planning and oversaw intellectual property (IP) strategy to support the clinical development of the Institute’s therapeutics. Before that, Dr. Dao investigated bacterial virulence and immunity to identify new vaccines against Tuberculosis as a postdoctoral fellow in an HHMI laboratory at Albert Einstein College of Medicine.
Currently, Dr. Dao also serves as a mentor for entrepreneurs participating in the Entrepreneurship Lab, a NYCEDC initiative. Dr. Dao received a Ph.D. in Molecular Genetics/Developmental Biology at Columbia University and a B.S. in Chemistry from University of Pittsburgh. Dr. Dao is also an alumnus of the Center for Biotechnology’s Fundamentals of the Bioscience Program in 2010.
“We are thrilled to have Dee join the Center for Biotechnology to lead our technology and business development efforts on behalf of innovators and emerging companies in New York” Diane Fabel, Director of Operations at the Center for Biotechnology said. She continued “Dee brings deep experience working with and funding innovation to her role at the Center which our clients and community will greatly benefit from.”
“I am very happy to join the team at the Center for Biotechnology. I’ve admired the work the Center for Biotechnology has done when it comes to supporting and accelerating the development of biomedical technology in New York State” Dr. Dao said. “I’m looking forward to helping lead the technology and business development efforts of the Center and increase the impact the organization can have on the wealth of innovations in the region”.
[post_title] => Dr. Dee Dao Appointed Associate Director for Business Development
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => dr-dee-dao-appointed-associate-director-for-business-development
[to_ping] =>
[pinged] =>
[post_modified] => 2025-02-24 12:42:43
[post_modified_gmt] => 2025-02-24 17:42:43
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://centerforbiotechnology.org/?p=4534
[menu_order] => 0
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[4] => WP_Post Object
(
[ID] => 2060
[post_author] => 3
[post_date] => 2015-12-14 20:06:35
[post_date_gmt] => 2015-12-14 20:06:35
[post_content] => Entrepreneur Derek Brand Selected to Facilitate New Bioscience Ventures
STONY BROOK, N.Y. – December 14, 2015 – The Center for Biotechnology at Stony Brook University announced today the appointment of Derek Brand as BioEntrepreneur-In-Residence (B-EIR) for the Long Island Bioscience Hub. The Long Island Bioscience Hub is a National Institutes of Health-designated Research Evaluation and Commercialization Hub, and represents a partnership between Stony Brook University, Cold Spring Harbor Laboratory, and Brookhaven National Laboratory, to commercialize technology emerging from their institutions.
Mr. Brand most recently served as Vice President of Business Development at Enumeral Biomedical Corp., which licensed a single cell immunology platform out of MIT and is now a publicly traded biotechnology company with a pipeline of novel immunotherapies in oncology. In addition to Enumeral, Mr. Brand has held both business and scientific roles at multiple early-stage, venture-backed biomedical startup companies; he has also held commercial leadership roles at GE and the New York Academy of Sciences and presently serves on the advisory board of Allovate LLC, a novel allergy immunotherapy company in NYC. He received his MBA from Babson College and his B.A. in biology from Hamilton College.
“I’m excited to take on the role of BioEntrepreneur-in-Residence and looking forward to bringing a diverse array of startup experience to the LIBH community” Mr. Brand stated. “The opportunity to dig in at the earliest stages of innovation with the exceptional scientists at Long Island institutions is a terrific opportunity, and it’s an honor to have been selected.”
“Mr. Brand is an excellent addition to the team of entrepreneurs engaged in the B-EIR initiative” Diane Fabel, Director of Operations for the Center for Biotechnology stated. “We are excited to see the positive impact these entrepreneurs will have as new companies are launched within the Hub.”
Mr. Brand joins an impressive roster of seven B-EIRs that was expanded in November to include Drs. Brian McCarthy and Gian Luca Araldi. Dr. McCarthy has an extensive background as an investment analyst and as the President and CEO of the startup Influmedix while Dr. Araldi has had a distinguished career in drug discovery within the pharmaceutical industry and as the Founder and Principal of US Pharma Services.
LIBH B-EIRs are tasked with identifying technology or technologies from within the partner institutions that will create the foundation for licensing and company formation. B-EIRs will have the support of the LIBH business and technology development staff, along with external industry advisors to develop successful commercialization strategies, and position the company for SBIR/STTR grant opportunities, and Angel and VC investment. The LIBH can also provide opportunities to access development funding to help advance technologies towards commercialization. Ultimately, the goal is to foster the creation and growth of new ventures that leverage the exceptional scientific and technological advances taking place at LIBH institutions.
[post_title] => Long Island Bioscience Hub Selects Third Bioentrepreneur-In-Residence
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => long-island-bioscience-hub-selects-third-bioentrepreneur-in-residence
[to_ping] =>
[pinged] =>
[post_modified] => 2016-03-29 20:14:04
[post_modified_gmt] => 2016-03-29 20:14:04
[post_content_filtered] =>
[post_parent] => 0
[guid] => http://centerforbiotechnology.org/?p=2060
[menu_order] => 194
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
)
[post_count] => 5
[current_post] => -1
[before_loop] => 1
[in_the_loop] =>
[post] => WP_Post Object
(
[ID] => 4804
[post_author] => 4
[post_date] => 2025-03-20 12:10:54
[post_date_gmt] => 2025-03-20 16:10:54
[post_content] =>
The Center for Biotechnology is pleased to announce a request for proposals for our Research Evaluation and Commercialization Hub (REACH) award program. Awards will be in two categories: Feasibility ($50k/12mo) and Proof of Concept ($100K/12 mo.) Details on the full funding program overview and proposal guidelines can be found here.
The development of promising innovations often stalls due to limited early-stage funding to address translational uncertainties. The Center for Biotechnology's Research Evaluation and Commercialization Hub (REACH) award program bridges the translation gap between biomedical discovery and their development toward commercial goals. Program funding is intended to determine feasibility, develop proof-of-concept, and ultimately lead to follow-on funding, a strategic partnership, or company formation.
The REACH program supports faculty and postdoctoral researchers in translating bio-based, bio-convergence, and bio-medical research discoveries by providing targeted funding and strategic guidance to bridge the translation gap between discovery and development for commercialization.